What the Intensivists Need to Know About Critically Ill Lymphoma Patients

  • Ranjit Nair
  • Krina Patel
Reference work entry


Lymphomas, both Hodgkin’s and non-Hodgkin’s, are the most common hematological malignancy. Management of acute complications is fundamental in reducing the morbidity and mortality in lymphoma care. Oncologic emergencies for patients with lymphoma include symptoms and signs related directly to the disease and/or to the treatment; many organs may be involved including, but not limited to, metabolic, renal, cardiovascular, neurologic, hematologic, and infectious complications. This review will focus on the numerous approaches that are aimed at managing these complications.


Hodgkin’s lymphoma Non-Hodgkin’s lymphoma Oncologic emergencies 


Conflicts of Interest

KP = research funds from Poseida, Intrexon/Ziopharm, Takeda. Advisory board/consultancy in Takeda, DAVA oncology, Celgene, Janssen, Amgen, BMS, and Oncopeptides.


  1. 1.
    Aapro M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Aksoy S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(7): 1307–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Astrom KE, et al. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin disease. Brain. 1958;81:93–111.CrossRefPubMedGoogle Scholar
  4. 4.
    Azoulay E, et al. Exacerbation with granulocyte colony-stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit Care Med. 2003;31:157–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Azoulay E, et al. Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med. 2002;30:781–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Azoulay E, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium – a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31(22):2810–8.CrossRefGoogle Scholar
  7. 7.
    Berger JR, et al. Progressive multifocal leukoencephalopathy. Semin Neurol. 1999;19(02):193–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Bontant T, Le Garrec S, Avran D, Dauger S. Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase. BMJ case reports, 2014, bcr2014204706.Google Scholar
  9. 9.
    Brizendine K, et al. Search of…. N Engl J Med. 2010;363(23):2249–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Cairo MS, et al. Incidence of treatment-related, laboratory and clinical tumor lysis syndrome. Blood. 2012;120:238.CrossRefGoogle Scholar
  11. 11.
    Canellos GP. Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci. 1974;230(1):240–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood. 2009;113(20):4834–40.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Castillo JJ, et al. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012;17:756.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chan FH, et al. Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature. Case Rep Med. 2009;2009:1.CrossRefGoogle Scholar
  15. 15.
    Clifford DB, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):115.CrossRefGoogle Scholar
  16. 16.
    Coiffier B, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16): 2767–78.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest. 1977;59:786.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cortes J, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone – results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    De Luca A, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008;22(14):1759–67.CrossRefPubMedGoogle Scholar
  20. 20.
    DeVita VT, Hellman S, Rosenberg SA. Cancer Principles and Practice in Oncology, 4th ed. 1993; vols 1 and 2.Google Scholar
  21. 21.
    Di Comite G, et al. Hypoglycaemia and lactic acidosis in a MALT non Hodgkin’s lymphoma. Leuk Lymphoma. 2002;43(6):1341–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Edeani A, Shirali A. Tumor Lysis Syndrome. Am Soc Nephrol. 2016;2016:9620520.Google Scholar
  23. 23.
    Engsig FN, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Eren S, et al. The superior vena cava syndrome caused by malignant disease: imaging with multi-detector row CT. Eur J Radiol. 2006;59(1):93–103.CrossRefPubMedGoogle Scholar
  25. 25.
    Fardet L, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014; 66(9):2613–20.CrossRefGoogle Scholar
  26. 26.
    Frat JP, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–96.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Freifeld AG, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases society of America. Clin Infect Dis. 2011;52(4):e56–93.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Friedenberg AS, et al. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine. 2007;86(4):225–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Glasheen J, Sorensen MD. Burkitt’s lymphoma presenting with lactic acidosis and hypoglycemia-a case presentation. Leuk Lymphoma. 2005;46(2):281–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Goldberg SL, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 2002;99:1486.CrossRefPubMedGoogle Scholar
  31. 31.
    Haapoja I, Blendowski C. Superior vena cava syndrome. Semin Oncol Nurs. 1999;183–189(7):15.Google Scholar
  32. 32.
    Hall CD, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med. 1998;338(19):1345–51.CrossRefPubMedGoogle Scholar
  33. 33.
    Halperin ML, et al. Rationale for the use of sodium bicarbonate in a patient with lactic acidosis due to a poor cardiac output. Nephron. 1994;66(3):258–61.CrossRefPubMedGoogle Scholar
  34. 34.
    He YF, et al. Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma. Adv Ther. 2007;24(3):505–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Hodby K, Fields PA. Management of lymphoma in pregnancy. Obstet Med. 2009;22(2):46–51.CrossRefGoogle Scholar
  36. 36.
    Howard SC, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95(4):563–73.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Howard SC. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hu MI, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metabol. 2014;99(9):3144–52.CrossRefGoogle Scholar
  39. 39.
    Hunter W. The history of an aneurysm of the aorta with some remarks on aneurysms in general. Med Observ Inquir (Lond) Med Obs Soc Phys Lond. 1957;1:323.Google Scholar
  40. 40.
    Itaya M, et al. A case of primary adrenal diffuse large B cell lymphoma presenting with severe hyponatremia. CEN Case Rep. 2016;5(1):91–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2008;2008:349–58.CrossRefGoogle Scholar
  42. 42.
    Kane E, et al. Emergency admission and survival from aggressive non-Hodgkin lymphoma: a report from the UK’s population-based Haematological Malignancy Research Network. Eur J Cancer. 2017;78:53–60.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Karlin L, et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant. 2005;36:245–50.CrossRefPubMedGoogle Scholar
  44. 44.
    Kawabata I, et al. MRI during pregnancy. J Perinat Med. 2003;31(6):449–58.CrossRefPubMedGoogle Scholar
  45. 45.
    Khatri BO, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402–9.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487–95.CrossRefPubMedGoogle Scholar
  48. 48.
    Knaus WA, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10): 818–29.CrossRefPubMedGoogle Scholar
  49. 49.
    Kocak MZ, et al. Superior vena cava syndrome and multiple venous thrombosis in a patient with B Cell Lymphoma. Althea Med J. 2018;5(1):12–5.CrossRefGoogle Scholar
  50. 50.
    Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193(1):1–6.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kuehnhardt D, et al. Therapeutic implication of BAL in patients with neutropenia. Ann Hematol. 2009;88(12): 1249–56.CrossRefPubMedGoogle Scholar
  52. 52.
    Kumar A, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010;38:1651–64.CrossRefPubMedGoogle Scholar
  53. 53.
    Legrand M, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43–9.CrossRefGoogle Scholar
  54. 54.
    LeGrand SB, et al. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149(4):259–63.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lerner RK, Pessach I, Rubinstein M, Paret G. Lactic Acidosis as Presenting Symptom of Thiamine Deficiency in Children with Hematologic Malignancy. Journal of Pediatric Intensive Care. 2017;6(02):132–5.Google Scholar
  56. 56.
    Levine D. Obstetric MRI. J Magn Reson Imaging. 2006;24(1):1–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Lyman GL. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–37.CrossRefPubMedGoogle Scholar
  58. 58.
    Martelli M, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113: 318–27.CrossRefPubMedGoogle Scholar
  59. 59.
    Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2): 558–67.CrossRefPubMedGoogle Scholar
  60. 60.
    Marzocchetti AN, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009;73(19):1551–8.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Mathieu D, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med. 1991;19(11):1352–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Mokart D, et al. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Med. 2015;41(2):296–303.CrossRefGoogle Scholar
  63. 63.
    Morin S, et al. Management of superior vena cava syndrome in critically ill cancer patients. Support Care Cancer. 2018;26(2):521–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Nair R, Shah U. Lactic acidosis: a rare oncological emergency in solid tumors at presentation. Am J Med Sci. 2017;353(4):402–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Onishi C, et al. Asian variant of intravascular large B cell lymphoma causes patients to frequently develop the syndrome of inappropriate antidiuretic hormone secretion. Ann Hematol. 2011;90(11):1293–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Park S, et al. Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat. 2015;47(3):448.CrossRefPubMedGoogle Scholar
  67. 67.
    Pecherstorfer M, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11(8):539.CrossRefPubMedGoogle Scholar
  68. 68.
    Pène F, et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008;36: 690–6.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Pereg D, et al. The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica. 2007;92(9):1230–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Ramos-Casals M, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–16.CrossRefGoogle Scholar
  71. 71.
    Rice TW, et al. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine. 2006;85(1):37–42.CrossRefPubMedGoogle Scholar
  72. 72.
    Schellongowski P, et al. Intensive care for cancer patients. Mag Eur Med Oncol. 2016;9(1):39–44.Google Scholar
  73. 73.
    Schuh AM, et al. Lactic acidosis in a critically ill patient: not always Sepsis. Pediatr Emerg Care. 2018;34(9):e165–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Segal RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7–30Google Scholar
  75. 75.
    Shallis RM, et al. Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: a retrospective review. Clin Lymphoma Myeloma Leuk. 2018;18(2):e123–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Soares M, et al. Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question. J Crit Care. 2010;25: 37–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Sonbol MB, et al. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol. 2013;88(2):152–4.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Spina M, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155–61.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Strewler GJ, Nissenson RA. Hypercalcemia in malignancy. West J Med. 1990;153(6):635.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Svahn J, et al. Severe lactic acidosis due to thiamine deficiency in a patient with B-cell leukemia/lymphoma on total parenteral nutrition during high-dose methotrexate therapy. J Pediatr Hematol Oncol. 2003;25(12):965–8.CrossRefPubMedGoogle Scholar
  82. 82.
    Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. J Oncol Pract. 2018;14(4): 250–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Teegala SR, et al. Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy. J Clin Oncol. 2007;25(18_suppl):19616.Google Scholar
  84. 84.
    Todeschini G, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Investig. 1999;29:453–7.CrossRefGoogle Scholar
  85. 85.
    Trifilio SM, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant. 2011;46:800.CrossRefPubMedGoogle Scholar
  86. 86.
    Verbalis JG. Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion. Endocrinol Nutr. 2010;57(Suppl 2):30–40.CrossRefPubMedGoogle Scholar
  87. 87.
    Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18–26.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Yeung SC, et al. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998;19(2): 144–72.CrossRefPubMedGoogle Scholar
  89. 89.
    Zavagli G, et al. Life-threatening hyponatremia caused by vinblastine. Med Oncol Tumor Pharmacother. 1988;5(1):67–9.PubMedGoogle Scholar
  90. 90.
    Zondek H, et al. Die bedeutung der calciumbestimmung im blute fur die diagnose der niereninsuffizienz. Z Klin Med. 1924;99:129–32.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ranjit Nair
    • 1
  • Krina Patel
    • 1
  1. 1.Department of Lymphoma and Myeloma, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations